logo-loader
RNS
Avacta Group PLC

Avacta Group PLC - New Response in Phase 1b Trial

RNS Number : 5471N
Avacta Group PLC
19 June 2025
 

Avacta Group plc

 

("Avacta" or the "Group" or the "Company")

 

New Response in the FAP-Dox (AVA6000) Phase 1b Trial

 

LONDON and PHILADELPHIA - June 19, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces a new partial response observed in a patient with salivary gland cancer (SGC) in the dose expansion phase of the FAP-Dox (AVA6000) Phase 1b trial. 

 

This further signal of antitumor activity in this disease setting is encouraging as the expansion cohort continues to enroll in the indication of salivary gland cancer. This patient is a 69-year-old male with metastatic salivary gland cancer.  His prior therapy includes surgery and radiation with no prior systemic therapy.  His combined tumor diameter was reduced at the first scan by almost 50%, qualifying as a partial response.

 

Recent data presented by the Company at the American Association of Cancer Research (AACR) annual meeting in April 2025 described the Phase 1a cohort of patients with one confirmed partial response and multiple minor responses with a disease control rate of 91%. At the time of the data cutoff, the median progression free survival had not been reached and the data are trending to a doubling of the benchmark PFS in this pretreated setting. Recent benchmark data were published at ESMO in 2024 (Licitra et al. ESMO Annual Congress 2024). The unmet need in this rare tumor type is very high, with metastatic salivary gland cancer having no preferred standard therapy.

 

The Company plans to publish the final data from the AVA6000 Phase 1a in the second half of 2025.  Further, the Company will provide a business update on the date of the Annual General Meeting, on July 2, 2025.

 

 

Christina Coughlin, CEO Avacta commented:

 

"We are thrilled to see the antitumor activity of FAP-Dox (AVA6000) in this disease with no preferred standard therapy.  The high unmet need in this indication underscores the potential for FAP-Dox to have a meaningful impact to patients.  We are encouraged by this response and remain focused on delivering further updates in this setting later in 2025."

 

  

-Ends-

 

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc

Michael Vinegrad, Group Communications

Director

www.avacta.com





Peel Hunt (Nomad and Joint Broker)

James Steel / Chris Golden

 

 

 

www.peelhunt.com

 

Panmure Liberum (Joint Broker)

Emma Earl / Will Goode / Mark Rogers

 

ICR Healthcare

Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 

www.panmureliberum.com

 

avacta@icrhealthcare.com

 

 

Investor Contact

Renee Leck

THRUST Strategic Communications

 

 

 

renee@thrustsc.com

 

Media Contact

Carly Scaduto

Carly Scaduto Consulting

 

Carly@carlyscadutoconsulting.com 

 

 

 

About Avacta - www.avacta.com

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGUGDLRXBDGUC
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read